Sun Pharma announced on Wednesday that it has signed an exclusive patent licensing agreement with Lundbeck of Denmark to market and distribute Vortioxetine, an antidepressant medication, in India under the brand name Vortidiftm.
The licensing agreement’s territory will be limited to India. Vortioxetine is a multimodal antidepressant that has been licensed for the treatment of Major Depressive Disorder (MDD) in adults.
Over 80 countries have given their approval to the product, including the United States, the European Union, Canada, and Australia.
“Sun Pharma is India’s leader in neuropsychiatry therapy, and we strive to provide novel medications that meet a need gap,” stated Kirti Ganorkar, Sun Pharma’s CEO of India Business.
“MDD is a significant and complicated illness,” Ganorkar said, “and Vortidiftm will be a vital new therapy option for patients in India.” MDD is one of the most common causes of disability, impacting 246 million individuals worldwide and 35 million in India.
MDD is marked by pronounced mood changes as well as distinct psychological and vegetative changes, such as sleep disturbances, appetite disturbances, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, difficulty maintaining mental focus, and suicidal thinking and behavior.
In India, Sun Pharma is the market leader in terms of prescriptions. Sun Pharma’s central nervous system (CNS) division aspires to bring new solutions to patients and health care professionals in India with a strong product range.
Sun Pharma is a worldwide pharmaceutical firm based in Mumbai, Maharashtra, that makes and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries.
With a total sales of about US$4.5 billion as of June 2021, it is India’s largest pharmaceutical firm and the world’s fourth-largest specialty generic pharmaceutical company. Psychiatry, anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental, and nutritional are among the therapeutic categories covered by the goods.
Lundbeck is a global pharmaceutical firm based in Denmark that specializes in the research, development, production, marketing, and sales of medications. Depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and migraine are among the ailments targeted by the company’s medications.
Lundbeck, headquartered in Copenhagen, Denmark, employs 5600 people in more than 50 countries and has more than 100 product registrations. They have manufacturing sites in Denmark, France, and Italy, as well as research centers in Denmark and the United States. In 2020, Lundbeck produced sales of DKK 17.7 billion.
Follow and connect with us on Facebook, LinkedIn&Twitter
